When it comes to viremia, or measurable viral levels in the bloodstream, the Human Immunodeficiency Virus (HIV) remains a major concern for world health. Despite the revolutionary impact of antiretroviral medication (ART), obstacles to adherence, viral reservoirs, and resistant virus strains continue to pose a threat to HIV treatment. Whether or not initial viremia is present, this article investigates the long-term efficacy of antiretroviral therapy. Our research delves at the inner workings of the virus, how long-acting antiretroviral therapy (ART) affects patients, and possible approaches to attaining long-term viral suppression. Examining the current literature critically reveals new information on viral reservoirs, medicines that improve adherence, and changing treatment paradigms.
Data sharing is not part of this study.
No conflicts of interest are reported by the authors.
The author takes full responsibility for the entire study process, including design, data collection, analysis, and manuscript writing.
This study did not receive specific financial support from funding agencies in the public, commercial, or non-profit sectors.
This article does not include any software or tools usage information.
I appreciate the assistance and expertise provided by everyone involved in this research and manuscript, and the valuable comments from peer reviewers.
-